clinical trial · NCT06120842
Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution
CataractGlaucomaOcular HypertensionBimatoprost Implant System (High Dose)Bimatoprost Implant System (Low Dose)Timolol Maleate Ophthalmic Solution, 0.5%Commercially Available Aspheric Monofocal Non-Yellow Chromophore IOLSpyGlass IOL
brief summary
This trial is a randomized study to evaluate and compare two doses of the Bimatoprost Implant System used in combination with the SpyGlass IOL to Timolol Ophthalmic Solution in participants with mild to moderate open-angle glaucoma or ocular hypertension undergoing cataract surgery.
started
Oct 13, 2023
primary completion
Jan 31, 2025
completion
Nov 1, 2027
last updated
Aug 22, 2025
official title
A Prospective, Multicenter, Randomized, Masked, Controlled Study to Evaluate the Safety, Efficacy, and Dose-response of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Maleate Ophthalmic Solution, USP, 0.5%
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol